Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries, today announced strongly accelerating orders for its UltraShear(TM)-processed Nano-CBD topical spray product. According to the update, the company has received seven initial market-seeding orders for UltraShear Nano-CBD from five new and two existing distributors in the three weeks following PBIO’s expansion into phase 2 of its commercial roll out.
“As previously explained, we strongly believe the marketplace has long been looking for a higher quality, effective, suitably nanoemulsified CBD product that can finally deliver fast and potent topical absorption of targeted benefits to users. The immediate response received from knowledgeable and experienced distributors, once they have been introduced to UltraShear Nano-CBD, has fully confirmed our expectations – they quickly ask for the opportunity to market our UltraShear-processed product,” said John B. Hollister, director of marketing and sales. “We are confident that the powerfully differentiated consumer experience will provide the all-important adoption driver complementing our sales and marketing efforts. Our team will be attending multiple key industry meetings to facilitate greater UltraShear exposure to key CBD industry players and to add additional distributors. Our goal is to expand to 25 distributors prior to year-end and 50 within 12 months. We believe each distributor will generate hundreds of thousands of dollars in annual revenue. Five new distributors and $300,000 in incremental revenue has been a gratifying start in the three-week period since launching our accelerated roll-out phase, but we believe it is just the ‘tip of the iceberg.’”
To view the full press release, visit https://ibn.fm/d05Qy
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Its products utilize both constant and alternating pressure. The company’s patented enabling technology platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterrorism applications. The company has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing it to enter the bio-pharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) (UltraShear(TM)) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
